SSY Group (02005): Obtained the drug production registration approval for Methylphenidate Sulfate tablets (100mg and 50mg) from the National Medical Products Administration.

SSY Group (02005) announced that the group has obtained the drug production registration certificate for Methysergide Sandamide Tablets (100mg and 50mg) from the National Medical Products Administration (NMPA) of China. This belongs to category 4 of chemical drugs, considered approved through consistency evaluation, making it the third domestic enterprise to receive approval. Methysergide Sandamide Tablets are mainly used for the combination therapy of adult patients with primary Parkinson's disease accompanied by symptoms fluctuation, in combination with other Parkinson's disease drugs such as Levodopa. The group's Methysergide Sandamide active pharmaceutical ingredient has been approved and registered by the NMPA for use in marketed formulations. The board of directors also happily announced that the group has obtained the NMPA's approval for the inhalation solution of Budesonide Hydrochloride (0.3ml: 30g), which belongs to category 3 of chemical drugs and is considered approved through consistency evaluation. The Budesonide Hydrochloride inhalation solution is mainly used for relieving various symptoms based on airflow restriction in patients with bronchial asthma, chronic bronchitis, and emphysema.